Introduction PARP inhibitors (PARPi) are a standard-of-care (SoC) treatment option for
patients with metastatic castration-resistant prostate cancer (mCRPC). Several clinical trials …

Context Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein
overexpressed in most prostate cancers and exploited as a target for PSMA-targeted …

Background Patients with metastatic castration-resistant prostate cancer (mCRPC) and
BRCA alterations have poor outcomes. MAGNITUDE found patients with homologous …

Simple Summary Castration-resistant prostate cancer (CRPC) remains a significant medical
challenge, even with recent advancements in diagnosis and treatment. To improve patient …

Simple Summary Recent practice-changing trials have highlighted the importance of
polyadenosine diphosphate-ribose polymerase inhibitors (PARPi) in metastatic castrate …

The clinical utility of circulating tumor cells (CTC) as a non-invasive multipurpose biomarker
is broadly recognized. The earliest methods for enriching CTCs from whole blood rely on …

The therapeutic landscape of metastatic hormone sensitive and metastatic castration-
resistant prostate cancer (mCRPC) is rapidly changing. We reviewed the current treatment …

Prostate cancer (PCa) is the most common cancer in men worldwide. Despite better and
more intensive treatment options in earlier disease stages, a large subset of patients still …

PARPi, in combination with ionizing radiation, has demonstrated the ability to enhance
cellular radiosensitivity in different tumors. The rationale is that the exposure to radiation …

Simple Summary Metastatic prostate cancer (mPCa) results in high mortality and there are
no effective treatments. The molecular mechanisms mediating the transition of early-stage …